The Case of the Missing Mole: When costly Lost or Missing Laboratory Test Samples Instigate Courier Management Redesign

Incidents of lost or missing laboratory test samples carry heavy consequences. Yet, many laboratories find that accountability, reconciliation, and tracking persist as issues. This white paper will be useful for laboratory directors, lab managers, courier managers, logistics managers, and outreach managers—whether in hospital-based laboratories or independent medical laboratories working as outreach labs—who employ and manage couriers in-house.

Anatomic Pathology: New Drivers Pushing Beyond Cloud to SaaS Laboratory Information Systems

This white paper will assist pathology leaders in gaining a complete understanding of how a true SaaS LIS can overcome today’s pathology laboratory challenges while making key points to include in your organization’s internal cloud discussions. In addition, you’ll walk away with a better understanding of where your pathology laboratory stands with respect to its own cloud journey.

Repurposing Your Lab’s Leftover COVID-19 Samples: Building New Revenue and Better Patient Outcomes Through Collaboration with Life Sciences

This free Dark Daily white paper for laboratory professionals explores how the rapid decline in SARS-CoV-2 testing affects molecular laboratories and the life sciences industry as a whole and offers opportunities for drug developers and labs to work together in new and beneficial ways.

2021 Forecast
Clinical Laboratories Use Automation to Expand Their Data Capabilities and Strengthen Their Resilience to Respond Faster During a Pandemic and Beyond

To address labs’ dire need for clean and reliable data, Dark Daily is pleased to offer this new FREE white paper for laboratory professionals that explains the key steps—and positive results—of strengthening the data service infrastructure of your clinical lab.

Molecular Testing for Urinary Tract Infection (UTI): 2020 Update on Clinical Utility and Reimbursement Trends

Molecular tests are becoming more routine as diagnostic tools, with many now covered by Medicare and commercial insurers. Advantages of molecular tests based on PCR technology include their ability to identify uropathogens traditionally missed by culture-based tests.

Driven by urgent, unmet analytical and clinical care needs, the adoption of the rapid molecular test—particularly RT-PCR for urinary tract infection control and treatment—has important implications.